Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Amphotericin B | Research

Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study

Authors: Larissa D. L. N. Costa, Uiara S. Lima, Vandilson Rodrigues, Mayara I. S. Lima, Lucilene A. Silva, Jorim Ithamar, Conceição M. P. S. Azevedo

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Objective

Visceral leishmaniasis (VL) is an endemic parasitic disease in Latin America, and its clinical picture is aggravated in coinfections with the human immunodeficiency virus (HIV). The objective of this study was to investigate clinical factors and laboratory variables associated with VL relapse and death in VL/HIV coinfected patients.

Methods

A prospective longitudinal study was conducted from January 2013 to July 2020 among 169 patients coinfected with VL and HIV. The outcomes investigated were the occurrence of VL relapse and death. Chi-square test, Mann–Whitney test and logistic regression models were used for statistical analysis.

Results

The occurrence rates were 41.4% for VL relapse and 11.2% for death. Splenomegaly and adenomegaly were associated with the increased risk of VL relapse. Patients with VL relapse had higher levels of urea (p = .005) and creatinine (p < .001). Patients who died had lower red blood cell counts (p = .012), hemoglobin (p = .017) and platelets (p < .001). The adjusted model showed that antiretroviral therapy for more than 6 months was associated with a decrease in VL relapse, and adenomegaly was associated with an increase in VL relapse. In addition, edema, dehydration, poor general health status, and paleness were associated with an increase in hospital death.

Conclusion

The findings suggest that adenomegaly, antiretroviral therapy, and renal abnormalities can be associated with VL relapse, while hematological abnormalities, and clinical manifestations like paleness, and edema can be associated with an increased odds of hospital death.
Trial registration number: The study was submitted to the Ethics and Research Committee of the Federal University of Maranhão (Protocol: 409.351).
Literature
1.
go back to reference Azevedo TS, Lorenz C, Chiaravalloti-Neto F. Risk mapping of visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2019;52: e20190240.CrossRefPubMed Azevedo TS, Lorenz C, Chiaravalloti-Neto F. Risk mapping of visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2019;52: e20190240.CrossRefPubMed
4.
go back to reference Lima URS, Vanolli L, Moraes EC, Ithamar JS, Azevedo CMPES. Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on this protozoan infection? PLoS ONE. 2019;14:e0225875.CrossRef Lima URS, Vanolli L, Moraes EC, Ithamar JS, Azevedo CMPES. Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on this protozoan infection? PLoS ONE. 2019;14:e0225875.CrossRef
6.
go back to reference Sousa-Gomes ML, Romero GAS, Werneck GL. Visceral leishmaniasis and HIV/AIDS in Brazil: are we aware enough? PLoS Negl Trop Dis. 2017;11: e0005772.CrossRef Sousa-Gomes ML, Romero GAS, Werneck GL. Visceral leishmaniasis and HIV/AIDS in Brazil: are we aware enough? PLoS Negl Trop Dis. 2017;11: e0005772.CrossRef
7.
go back to reference Viana GMC, Silva MACN, Garcia JVS, et al. Epidemiological profile of patients co–infected with visceral leishmaniasis and HIV/AIDS in Northeast. Brazil Rev Soc Bras Med Trop. 2017;50:613–20.CrossRefPubMed Viana GMC, Silva MACN, Garcia JVS, et al. Epidemiological profile of patients co–infected with visceral leishmaniasis and HIV/AIDS in Northeast. Brazil Rev Soc Bras Med Trop. 2017;50:613–20.CrossRefPubMed
9.
go back to reference Ministério da Saúde, Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Leishmaniose visceral grave: normas e condutas. Brasília: Ministério da Saúde, Secretaria de Vigilância em Saúde; 2006. Ministério da Saúde, Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Leishmaniose visceral grave: normas e condutas. Brasília: Ministério da Saúde, Secretaria de Vigilância em Saúde; 2006.
10.
go back to reference Costa DL, Rocha RL, Chaves EB, Batista VG, Costa HL, Costa CH. Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software. Rev Soc Bras Med Trop. 2016;9(6):728–40.CrossRef Costa DL, Rocha RL, Chaves EB, Batista VG, Costa HL, Costa CH. Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software. Rev Soc Bras Med Trop. 2016;9(6):728–40.CrossRef
11.
go back to reference Porto CC. Exame clínico. 5a ed. Rio de Janeiro: Guanabara Koogan; 2008. Porto CC. Exame clínico. 5a ed. Rio de Janeiro: Guanabara Koogan; 2008.
13.
go back to reference Távora LG, Nogueira MB, Gomes ST. Visceral Leishmaniasis/HIV co–infection in northeast Brazil: evaluation of outcome. Braz J Infect Dis. 2015;19:651–6.CrossRefPubMedPubMedCentral Távora LG, Nogueira MB, Gomes ST. Visceral Leishmaniasis/HIV co–infection in northeast Brazil: evaluation of outcome. Braz J Infect Dis. 2015;19:651–6.CrossRefPubMedPubMedCentral
14.
go back to reference Santos GO, Jesus NPS, Cerqueira-Braz JV, Santos VS, Lemos LMD. Prevalence of HIV and associated factors among visceral leishmaniasis cases in an endemic area of Northeast Brazil. Rev Soc Bras Med Trop. 2019;52: e20180257.CrossRefPubMed Santos GO, Jesus NPS, Cerqueira-Braz JV, Santos VS, Lemos LMD. Prevalence of HIV and associated factors among visceral leishmaniasis cases in an endemic area of Northeast Brazil. Rev Soc Bras Med Trop. 2019;52: e20180257.CrossRefPubMed
15.
go back to reference Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Visceral leishmaniasis and HIV coinfection: current perspectives. HIV AIDS. 2018;10:193–201. Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Visceral leishmaniasis and HIV coinfection: current perspectives. HIV AIDS. 2018;10:193–201.
16.
go back to reference Guedes DL, Medeiros Z, Silva ED, et al. Visceral leishmaniasis in hospitalized HIV-infected patients in Pernambuco. Brazil Am J Trop Med Hyg. 2018;99:1541–6.CrossRefPubMed Guedes DL, Medeiros Z, Silva ED, et al. Visceral leishmaniasis in hospitalized HIV-infected patients in Pernambuco. Brazil Am J Trop Med Hyg. 2018;99:1541–6.CrossRefPubMed
17.
go back to reference Cloots K, Burza S, Malaviya P, et al. Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population–based with health facility–reported data. PLoS Negl Trop Dis. 2020;14: e0007995.CrossRefPubMedPubMedCentral Cloots K, Burza S, Malaviya P, et al. Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population–based with health facility–reported data. PLoS Negl Trop Dis. 2020;14: e0007995.CrossRefPubMedPubMedCentral
19.
go back to reference Zhang H, Zhao J, Wang P, Qiao Z. Effect of testosterone on Leishmania donovani infection of macrophages. Parasitol Res. 2001;87:674–6.CrossRefPubMed Zhang H, Zhao J, Wang P, Qiao Z. Effect of testosterone on Leishmania donovani infection of macrophages. Parasitol Res. 2001;87:674–6.CrossRefPubMed
22.
go back to reference Davy-Mendez T, Napravnik S, Zakharova O, et al. Acute HIV infection and CD4/CD8 ratio normalization after antiretroviral therapy initiation. J Acquir Immune Defic Syndr. 2018;79:510–8.CrossRefPubMedPubMedCentral Davy-Mendez T, Napravnik S, Zakharova O, et al. Acute HIV infection and CD4/CD8 ratio normalization after antiretroviral therapy initiation. J Acquir Immune Defic Syndr. 2018;79:510–8.CrossRefPubMedPubMedCentral
23.
go back to reference Alvar J, Cañavate C, Gutiérrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10:298–319.CrossRefPubMedPubMedCentral Alvar J, Cañavate C, Gutiérrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10:298–319.CrossRefPubMedPubMedCentral
24.
go back to reference Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Publ Heal. 2017;2:e35-46.CrossRef Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Publ Heal. 2017;2:e35-46.CrossRef
25.
go back to reference Hurissa Z, Gebre-Silassie S, Hailu W, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co–infection in northwest Ethiopia. Trop Med Int Health. 2010;15:848–55.CrossRefPubMed Hurissa Z, Gebre-Silassie S, Hailu W, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co–infection in northwest Ethiopia. Trop Med Int Health. 2010;15:848–55.CrossRefPubMed
26.
go back to reference Mohammed R, Fikre H, Schuster A, Mekonnen T, Griensven JV, Diro E. Multiple relapses of visceral leishmaniasis in HIV Co–Infected Patientes: a case series from Ethiopia. Curr Ther Res. 2020;92: 100583.CrossRefPubMedPubMedCentral Mohammed R, Fikre H, Schuster A, Mekonnen T, Griensven JV, Diro E. Multiple relapses of visceral leishmaniasis in HIV Co–Infected Patientes: a case series from Ethiopia. Curr Ther Res. 2020;92: 100583.CrossRefPubMedPubMedCentral
27.
go back to reference Fontoura I, Barbosa D, Andrade PAD, et al. Epidemiological, clinical and laboratory aspects of human visceral leishmaniasis (HVL) associated with human immunodeficiency virus (HIV) coinfection: a systematic review. Parasitol. 2018;145:1801–18.CrossRef Fontoura I, Barbosa D, Andrade PAD, et al. Epidemiological, clinical and laboratory aspects of human visceral leishmaniasis (HVL) associated with human immunodeficiency virus (HIV) coinfection: a systematic review. Parasitol. 2018;145:1801–18.CrossRef
28.
go back to reference Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India. Clin Infect Dis. 2015;61:1255–62.CrossRefPubMedPubMedCentral Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India. Clin Infect Dis. 2015;61:1255–62.CrossRefPubMedPubMedCentral
29.
go back to reference Cota GF, De Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011;5: e1153.CrossRefPubMedPubMedCentral Cota GF, De Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011;5: e1153.CrossRefPubMedPubMedCentral
30.
go back to reference Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study. PLoS Negl Trop Dises. 2015;9: e0004087.CrossRef Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study. PLoS Negl Trop Dises. 2015;9: e0004087.CrossRef
31.
go back to reference Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19:1–8.CrossRef Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19:1–8.CrossRef
Metadata
Title
Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study
Authors
Larissa D. L. N. Costa
Uiara S. Lima
Vandilson Rodrigues
Mayara I. S. Lima
Lucilene A. Silva
Jorim Ithamar
Conceição M. P. S. Azevedo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08009-1

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.